Miller K, Klauber G T
Department of Pediatrics, Lutheran General Hospital, Park Ridge, Illinois.
Clin Ther. 1990 Jul-Aug;12(4):357-66.
Desmopressin acetate, a synthetic antidiuretic drug, was evaluated in two US multicenter studies involving a total of 176 children with severe primary nocturnal enuresis. Patients who qualified during the screening period, entered a double-blind treatment phase during which they received 20 micrograms or 40 micrograms of desmopressin acetate or placebo at bedtime for four weeks. This phase was followed by a four-week open-label period, during which all patients received 20 or 40 micrograms of desmopressin acetate. In both studies, children given desmopressin acetate had significantly fewer wet nights after two and four weeks of therapy than did children given placebo. During the open-label period, patients crossed over from placebo to desmopressin acetate showed similar reductions in enuresis. Global evaluations by the patients, their parents, or the investigators further confirmed the good results with desmopressin acetate. No serious adverse experiences were reported. Thus the results of these studies corroborate previously published reports of the efficacy and safety of desmopressin acetate in the treatment of primary nocturnal enuresis.
醋酸去氨加压素是一种合成抗利尿药物，在美国两项多中心研究中对其进行了评估，这两项研究共涉及176名重度原发性夜间遗尿症儿童。在筛查期符合条件的患者进入双盲治疗阶段，在此期间，他们在睡前接受20微克或40微克醋酸去氨加压素或安慰剂，为期四周。该阶段之后是为期四周的开放标签期，在此期间所有患者接受20或40微克醋酸去氨加压素。在两项研究中，接受醋酸去氨加压素治疗的儿童在治疗两周和四周后尿床次数明显少于接受安慰剂治疗的儿童。在开放标签期，从安慰剂组转至醋酸去氨加压素组的患者遗尿情况也有类似改善。患者、其父母或研究人员的总体评估进一步证实了醋酸去氨加压素的良好疗效。未报告严重不良事件。因此，这些研究结果证实了先前发表的关于醋酸去氨加压素治疗原发性夜间遗尿症疗效和安全性的报告。
